Brontictuzumab

Brontictuzumab (INN; development code OMP-52M51) is a humanized monoclonal antibody designed for the treatment of cancer.^[1][2]

Brontictuzumab

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	Notch 1
Clinical data
Other names	OMP-52M51
ATC code	none
Identifiers
CAS Number	1447814-75-6
ChemSpider	none
UNII	UNY2TQA40E
KEGG	D11229
Chemical and physical data
Formula	C6392H9862N1980O1710S50
Molar mass	143410.36 g·mol−1

It blocks the NOTCH1 receptor.^[3]

This drug was developed by OncoMed Pharmaceuticals.